Latest Regulatory News

Novo Resources has responded to an ASX price query, attributing recent share price and volume spikes to insider buying and rising gold prices, while confirming no undisclosed material information.

Insignia Financial has responded to ASX concerns over past disclosures of performance rights, affirming shareholder approvals and outlining improved compliance measures.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Multistack International Limited reported a net operating cash outflow of A$196,577 for the December quarter but maintains a solid cash buffer as it pursues the sale of its Australian subsidiary.

Multistack International Limited has announced plans to discontinue its current business operations and is working towards disposing of its Australian subsidiary after continued losses and cash burn.

Cyprium Metals is advancing its brownfield restart of the Nifty Copper Complex in Western Australia, targeting mid-2026 copper cathode production with a low-capital, high-cash-flow approach. The company has secured $41 million through an institutional placement and entitlement offer to fund exploration and expansion.

Marvel Gold Limited has pinpointed five high priority gold targets at its Hanang Project in Tanzania from initial drone magnetic survey data, setting the stage for a maiden drilling campaign in early 2026.

ReadCloud Limited has secured over 50 new school contracts for 2026, driving strong growth in its VET-in-Schools and eBooks divisions despite ongoing funding challenges in its Industry Training segment.

Impact Minerals has acquired a 55 sq km tenement covering the historic Huonville gold district near Broken Hill, significantly expanding its landholding and advancing its exploration for copper-gold deposits.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Riversgold Ltd has affirmed the material significance of its recent Northern Zone gold exploration results alongside a $2 million capital raising, assuring compliance with ASX continuous disclosure rules.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.